Abstract: Cosmetic or dermatological gel creams of the oil-in-water type, comprising (i) up to 90% by weight of a water phase, (ii) up to 20% by weight of a lipid phase, based on the total weight of the preparations, (iii) up to 5% by weight of one or more emulsifiers, (iv) also comprising up to 5% by weight of one or more ammonium acryloyldimethyltaurates/vinylpyrrolidone copolymers.

Abstract: The invention concerns cosmetic compositions containing, in a cosmetically acceptable medium, as thickening system: (A) at least a non-ionic associative polyurethane and (B) at least a non-ionic polymer comprising at least a fatty chain.

Abstract: Polyanhydrides which link low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into polymeric drug delivery systems are provided. Also provided are methods of producing polymeric drug delivery systems via these polyanhydride linkers as well as methods of administering low molecular weight drugs to a host via the polymeric drug delivery systems.

Abstract: An environmentally friendly method of loading nicotine onto cation exchange resins under anhydrous conditions is described. The method eliminates many of the processing problems that are associated with loading in aqueous media.

Abstract: The invention provides suspensions of micronized fenofibrate. The suspensions can comprise micronized fenofibrate in a solution of hydrophilic polymers. The suspensions can further comprise one or more surfactants.

Abstract: An antibacterial liquid dish cleaning composition with desirable cleansing properties comprising a C8-18 ethoxylated alkyl ether sulfate, two anionic surfactant, a betaine surfactant, a hydroxy containing organic acid, an organic thickener, polyethylene glycol and water.

Abstract: Disclosed is a dermal barrier composition which contains a hydrophilic polymer emulsion and a hydrophobic polymer emulsion. The dermal barrier composition is moisture activated, and remains inert until the hydrophobic and hydrophilic polymer emulsions contact a suitable substrate such as human skin. The dermal barrier composition is itself an emulsion, and can optionally contain a biocidal agent for antimicrobial and antiviral efficacy. The dermal barrier composition can also contain other active agents such as sunscreens, insect repellents and fungicides. The dermal barrier composition can be applied topically to skin, where it forms a protective or barrier layer against a number of pathogenic and chemical irritants.

Abstract: A forming oil-in-water emulsion in the form of a cream comprising, in an aqueous medium, at least: a) from 5 to 20% of an exclusively nonionic surfactant system comprising at least one foaming nonionic surfactant; b) from 10 to 50% of an oily phase containing at least one water-insoluble oil whose solubility parameters dD, dP and dH according to Hansen's solubility space satisfy the conditions: 15.5 (J/cm3)½≦dD≦18.0 (J/cm3)½ and 0 (J/cm3)½≦dA≦6.5 (J/cm3)½ with dA=(dP2+dH2)½ c) and, as a gelling agent, at least one crosslinked homopolymer or copolymer formed from at least one cationic or anionic monomer containing ethylenic unsaturation and from a crosslinking agent containing polyethylenic unsaturation. This composition is useful in cosmetics, dermatology and hygiene as a base for cleansing products for the skin, the hair, the mucous membranes and the scalp.

Abstract: A mating disruption method for the control of insect pests comprises releasing a sex pheromone in a field wherein an adsorption of the sex pheromone to a soil in the field is decreased.

Abstract: Bioadhesive compositions in a flexible, finite form for topical application to skin or mucous membranes comprising a composition which results from an admixture of at least one PVP polymer, at least one bioadhesive, optionally a pharmaceutically acceptable solvent suitable for use with an active agent, and methods of administering active agents to a subject, are disclosed. The bioadhesive composition can either include an active agent incorporated directly in the composition, or a separate source of an active agent.

Abstract: A dilatant composition comprises (A) an o/w emulsion comprising an ionic surfactant, a water phase, and an oil phase which comprises a ceramide or a linear or branched, saturated or unsaturated C12-C32 fatty acid, wherein the oil phase is in a form of oil droplets having an average droplet size of from 0.01 to 0.2 &mgr;m; and (B) a nonionic, water-soluble polymer having an average molecular weight of at least 300,000.

Abstract: The present invention relates to a formulation and process for preparing dexibuprofen soft gelatin capsules comprising dexibuprofen dissolved in diethylene glycol monoethylether. The dexibuprofen-containing soft gelatin capsule includes a substantially clear solution of about 40% by weight of dexibuprofen, about 40% by weight of a solubilizer, about 0.8% to 5% be weight of surfactants, about 14% to 20% by weight of co-surfactants, about 2% by weight of a potassium salt generating species, and about 2% by weight of a viscosity imparter.

Abstract: The present invention is directed to compositions containing an acid precursor in amounts effective to inhibit microbial attachment and growth on a surface of a medical device having the composition applied thereto, to films of such compositions and to medical devices having the composition applied to a surface thereof.

Abstract: Antimicrobial/pharmaceutical preparations (e.g., solutions, gels, ointments, creams, sustained release preparations, etc.) which comprise chlorite (e.g., a metal salt of a chlorite) in combination with a peroxy compound (e.g., hydrogen peroxide), and methods for using such preparations for disinfection of articles or surfaces (e.g., contact lenses, counter tops, etc.), antisepsis of skin or other body parts, prevention or deterrence of scar formation and/or treatment and prophylaxis of dermal (i.e., skin or mucous membrane) disorders (e.g., wounds, burns, infections, cold sores, ulcerations, psoriasis, acne, or other scar-forming lesions).

Abstract: Polyanhydrides which link low molecular weight drugs containing a carboxylic acid group and an amine, thiol, alcohol or phenol group within their structure into polymeric drug delivery systems are provided. Also provided are methods of producing polymeric drug delivery systems via these polyanhydride linkers as well as methods of administering low molecular weight drugs to a host via the polymeric drug delivery systems.

Abstract: The present invention relates to orally administerable medicinal plant dry extracts, wherein the non-volatile phase of the extract is bound in a microdisperse form and/or in the form of a semisolid or solid solution to a first carrier which is soluble in or miscible with alcohol, soluble in or miscible with water and solid at room temperature, optionally in addition to other auxiliaries and/or additives. Optionally, a second carrier is selected from carriers which are insoluble in alcohol, insoluble in water or swellable in water and solid at room temperature, or alkaline earth metal and/or alkali metal carbonates including hydrogencarbonates.

Abstract: A method for increasing the stability of a food-grade or pharmaceutical-grade liquid, such as an extracted oil, herbal extract, flavor, color, or volatile chemical component used in the flavor industry, is provided. The method comprises mixing the liquid with an amphoteric polymer, preferably polyvinylpyrrolidone, to thereby infuse the liquid into the amphoteric polymer matrix and form a generally-solid, stabilized product. Optionally, bulking agents, absorbents, and flowing agents can be mixed with the liquid and amphoteric polymer to enhance the properties of the stabilized product. The inventive method is particularly useful for entrapping liquids that are highly volatile, heat sensitive and/or easily oxidizable.

Abstract: This invention provides carrier systems useful in preparing pharmaceutical formulations, the systems comprising, by weight percentage, from about 1% to about 20%, preferably from about 5% to about 12%, of a surfactant component; from about 55% to about 93%, preferably from about 60% to about 85%, of a component of one or more polyethylene glycols (PEG); and from about 1% to about 25%, preferably from about 5% to about 15%, of one or more sucrose fatty acid esters or polyvinylpyrrolidone (PVP) with a K value between about 15 and about 90, preferably with a K value of from about 16 to about 18, most preferably about 17, as defined in USP/NF, or a combination of one or more sucrose fatty acid esters or PVP, and, optionally, one or more pharmaceutically acceptable preservatives or antioxidants, such as BHA, BHT, ascorbyl palmitate or benzyl alcohol.

Abstract: A process for treating balding spots and a composition which when applied to areas of thinning or balding hair increases the width and visibility of the hairs within the thinning or balding area and thus obscures visibility of the scalp or skin underlying the hairs. A bonding agent helps make the spray more efficient in application, decreases undesirable overspray, and increases formula adherence to hair shafts.

Abstract: The present invention relates to a liquid dual phase cosmetic or pharmaceutical composition comprising an oil phase and an aqueous phase, the composition containing as a demixing agent a film forming agent such as polyvinylpyrrolidone and derivatives thereof. The compositions of the invention are particularly useful as makeup removers.

Abstract: A method for preparing a hydroxyapatite composite is disclosed. This method comprises alternately soaking a matrix which has been made hydrophilic at least on its surface, in a calcium ion aqueous solution containing calcium ions and substantially free of phosphate ions and in a phosphate ion aqueous solution containing phosphate ions and substantially free of calcium ions to securely form hydroxyapatite at least on the surface of the matrix. Also disclosed is a biocompatible material composed of the hydroxyapatite composite obtained by the method.

Abstract: A formulation of a 5&agr;-reductase inhibitor for oral administration, which comprises a composition obtained by grinding a mixture of an azasteroid, a water-soluble polymer and a disintegrant.

Abstract: Gel for local treatment of skin diseases and for prophylaxis, characterized by containing more than 90% of a drying and/or protein coagulating, short-chained alcohol or alcohol mixture, primarily ethanol, and possibly adjuvants or additives and by containing a gelling agent, that possesses good skin-adhesive properties, that gives a matrix formation of alcohol or alcohol mixtures, that creates an evaporation inhibiting effect, gives a prolonged effect, and form a protective plaster when the gel has dried.

Abstract: Non-staining topical iodine disinfecting compositions having the ability to inactivate pathogens associated with skin infections or diseases. based upon the presence of molecular iodine in a concentration above at least 15 ppm. Any other iodine species selected from the group consisting of complexed iodine and triiodide may be present with the total of such other iodine species limited to a concentration of less than about 700 ppm so that any visible stain resulting from the application of this composition on the skin will dissipate without leaving any visible skin coloration.

Abstract: Pharmaceutical compositions of 4-(5-cyclopentyloxycarbonylamino-1-methylindol-3-ylmethyl)-3-methoxy-N-o-tolylsulfonylbenzamide and a gelling agent, in particular hydroxypropylmethylcellulose, are described for treating asthma and related diseases. Processes for the preparation of the compositions are described.

Abstract: A method for alleviating the symptoms of a cosmetic or dermatologic skin condition is described. An effective amount of a poly(hydroxy acid)/polymer conjugate in a pharmaceutically or cosmetically acceptable vehicle is provided. Topical compositions of the conjugates with another cosmetic or dermatological agent, and compounds of the conjugates having attached physiologically active functional groups, are also provided.

Abstract: Liquid softgel fill formulations containing ibuprofen in free acid form, and softgel capsules comprised of a gelatin sheath enclosing such fill formulations, are prepared by dissolving more than 30% of ibuprofen in free acid form in polyethylene glycol and at least 10% by weight of a polyvinylpyrrolidone having an average molecular weight of from about 2,000 to about 54,000. The formulations may also include a surfactant to increase the bioavailability of the ibuprofen.

Abstract: A solid pharmaceutical preparation comprising a pharmaceutically active ingredient, erythritol, crystalline cellulose and an disintegrants, which exhibits a fast buccal disintegratability and dissolubility.

Abstract: The present invention provides a method of arresting, preventing and/or reversing the impairment of central and peripheral nervous system function comprising reducing insoluble protein deposit burden by the administration of branched polycationic compounds and pharmaceutical compositions containing such branched polycationic compounds. The compounds used in the preferred method of the invention are branched dendritic polycations.